{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Omega-3+Polyunsaturated+Fatty+Acids",
    "query": {
      "intervention": "Omega-3 Polyunsaturated Fatty Acids"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 510,
    "total_pages": 51,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Omega-3+Polyunsaturated+Fatty+Acids&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-18T07:31:04.302Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05457023",
      "title": "Plasma Neurofilament Light and Its Relationship With Omega-3 Status and Soccer Heading in Women Soccer Players",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Brain Trauma"
      ],
      "interventions": [
        {
          "name": "Plasma Neurofilament Light (NF-L)",
          "type": "OTHER"
        },
        {
          "name": "Omega-3 Index",
          "type": "OTHER"
        },
        {
          "name": "HeadCount Questionnaire",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "25 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 25 Years · Female only"
      },
      "enrollment_count": 27,
      "start_date": "2022-07-28",
      "completion_date": "2023-11-09",
      "has_results": false,
      "last_update_posted_date": "2023-11-13",
      "last_synced_at": "2026-09-18T07:31:04.302Z",
      "location_count": 2,
      "location_summary": "Kansas City, Missouri",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05457023"
    },
    {
      "nct_id": "NCT01526824",
      "title": "Lovaza's Effect on Clopidogrel in a Neuro Population",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Ischemic Stroke",
        "Transient Ischemic Attack"
      ],
      "interventions": [
        {
          "name": "omega-3 polyunsaturated fatty acids (Lovaza)",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Millard Fillmore Gates Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "25 Years to 80 Years"
      },
      "enrollment_count": 60,
      "start_date": "2011-09",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2012-02-06",
      "last_synced_at": "2026-09-18T07:31:04.302Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01526824"
    },
    {
      "nct_id": "NCT00360217",
      "title": "The Triglyceride Lowering Effect of an Omega-3 Fat (DHA) in Addition to Statin Therapy for Patients With CAD or Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hypertriglyceridemia (TG>200<500)",
        "Hyperlipidemia",
        "Coronary Artery Disease",
        "Coronary Risk Equivalent",
        "Diabetes"
      ],
      "interventions": [
        {
          "name": "docosahexanoic acid (DHA)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Maine Center for Lipids and Cardiovascular Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "21 Years to 80 Years"
      },
      "enrollment_count": 60,
      "start_date": "2006-01",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2011-11-18",
      "last_synced_at": "2026-09-18T07:31:04.302Z",
      "location_count": 1,
      "location_summary": "Scarborough, Maine",
      "locations": [
        {
          "city": "Scarborough",
          "state": "Maine"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00360217"
    },
    {
      "nct_id": "NCT02103842",
      "title": "Omega-3 Fatty Acids to Combat Sarcopenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sarcopenia"
      ],
      "interventions": [
        {
          "name": "Omega-3 fatty acids",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 24,
      "start_date": "2014-03",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2015-12-24",
      "last_synced_at": "2026-09-18T07:31:04.302Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02103842"
    },
    {
      "nct_id": "NCT01429454",
      "title": "NAPLS Omega-3 Fatty Acid Versus Placebo Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Psychosis"
      ],
      "interventions": [
        {
          "name": "Omega-3 Long Chain Fatty Acid",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "12 Years to 30 Years"
      },
      "enrollment_count": 127,
      "start_date": "2011-08",
      "completion_date": "2016-06",
      "has_results": true,
      "last_update_posted_date": "2021-02-25",
      "last_synced_at": "2026-09-18T07:31:04.302Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • San Diego, California • New Haven, Connecticut + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01429454"
    },
    {
      "nct_id": "NCT01242527",
      "title": "Epanova® for Lowering Very High Triglycerides",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Severe Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "omefas",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 399,
      "start_date": "2011-01",
      "completion_date": "2012-04",
      "has_results": true,
      "last_update_posted_date": "2016-08-04",
      "last_synced_at": "2026-09-18T07:31:04.302Z",
      "location_count": 30,
      "location_summary": "National City, California • Sacramento, California • Manchester, Connecticut + 25 more",
      "locations": [
        {
          "city": "National City",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Manchester",
          "state": "Connecticut"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01242527"
    },
    {
      "nct_id": "NCT00004448",
      "title": "Alternate Day Prednisone or Daily Fish Oil Supplements in Patients With Immunoglobulin A Nephropathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "IgA Glomerulonephritis"
      ],
      "interventions": [
        {
          "name": "omega-3 fatty acids",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "Up to 40 Years"
      },
      "enrollment_count": 96,
      "start_date": "1997-11",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2025-05-04",
      "last_synced_at": "2026-09-18T07:31:04.302Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004448"
    },
    {
      "nct_id": "NCT03313076",
      "title": "Vitamin D and n-3 Polyunsaturated Fatty Acids (PUFAs) to Prevent Chronic Pain Following Major Thermal Burn Injury",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Pain Following Thermal Burn Injury"
      ],
      "interventions": [
        {
          "name": "Omega-3 fatty acids (fish oil)",
          "type": "DRUG"
        },
        {
          "name": "Vitamin D3 (cholecalciferol)",
          "type": "DRUG"
        },
        {
          "name": "Vitamin D3 (cholecalciferol) placebo",
          "type": "DRUG"
        },
        {
          "name": "Omega-3 fatty acid placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2018-07-19",
      "completion_date": "2020-07-31",
      "has_results": true,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-09-18T07:31:04.302Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03313076"
    },
    {
      "nct_id": "NCT01180764",
      "title": "Effects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in Hypertriglyceridemia",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "Lovaza (Omega-3 acid ethyl esters)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "35 Years to 75 Years"
      },
      "enrollment_count": 0,
      "start_date": "2010-08",
      "completion_date": "2012-10",
      "has_results": false,
      "last_update_posted_date": "2016-02-08",
      "last_synced_at": "2026-09-18T07:31:04.302Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01180764"
    },
    {
      "nct_id": "NCT04006847",
      "title": "Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myeloid Leukemia, Chronic Phase"
      ],
      "interventions": [
        {
          "name": "Eicosapentaenoic Acid",
          "type": "DRUG"
        },
        {
          "name": "Tyrosine kinase inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2020-09-14",
      "completion_date": "2021-05-21",
      "has_results": true,
      "last_update_posted_date": "2022-07-01",
      "last_synced_at": "2026-09-18T07:31:04.302Z",
      "location_count": 1,
      "location_summary": "Hershey, Pennsylvania",
      "locations": [
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04006847"
    }
  ]
}